Background: Esophagectomy is frequently accompanied by substantial complications with secondary disturbance of the immune system. After esophagectomy for adenocarcinoma of the distal esophagus and/or gastroesophageal junction, the majority of patients develops an early recurrence and dies within 2 years. The aim of this study was to determine the relevance of perioperative complications on the timing of death due to recurrence.
Methods: A consecutive series of 351 patients who underwent esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction was reviewed.
Results: Of the 351 included patients, 191 patients (54%) died due to recurrence of esophageal adenocarcinoma. Of these 191 patients, 77 (40%), 138 (72%), and 186 patients (97%) died before 12, 24, and 60 months, respectively. Multivariate Cox regression analysis demonstrated that T-stage, lymph node ratio >0.20, the presence of extracapsular lymph node involvement, but not complications were significant factors for the prediction of death due to cancer recurrence. However, in the patients who died, multivariate Cox regression analysis demonstrated that not only the presence of extracapsular lymph node involvement but also the occurrence of complications were significantly related with a shorter time interval until death due to recurrence.
Conclusion: The relation between perioperative complications and cancer recurrence per se is not causal. However, postoperative complications are independently associated with the early timing of death due to cancer recurrence. A possible explanation for this phenomenon is that immunologic host factors enhance microscopic residual disease to develop more rapidly into clinically manifest recurrence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SLA.0b013e31815b695e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Long-Term Survival in Esophagogastric Junction Cancer with Multiple Lymph Node Metastasis Through Pre-and-Post Operative Chemotherapy].
Gan To Kagaku Ryoho
December 2024
Dept. of Surgery, Yanagawa Hospital.
A 62-year-old man was diagnosed with Stage Ⅲ signet ring cell carcinoma of the lower thoracic esophagus. The patient underwent 2 courses of neoadjuvant cisplatin and 5-fluorouracil(SP therapy), demonstrating stable efficacy. Subsequently, the patient underwent subtotal esophagectomy with thoracoabdominal 2-field lymphadenectomy via right thoracotomy, followed by esophageal reconstruction using a gastric tube through a retrosternal route.
View Article and Find Full Text PDFAdjuvant Therapy after Esophagectomy for Esophageal Cancer: Who Needs It?: Multi-institution Worldwide Observational Study.
Ann Surg Open
December 2024
Division of Biostatistics, Department of Public Health Sciences, University of Miami, Miami, FL.
Objective: Based on current practice guidelines, we hypothesized that most patients with esophageal cancer, particularly those with locally advanced cancer, would benefit from adjuvant therapy after esophagectomy esophagectomy alone. We sought to obtain a granular estimate of patient-level risk-adjusted survival for each therapeutic option by cancer histopathology and stage.
Background: Although esophagectomy alone is now an uncommon therapy for treating locally advanced esophageal cancer, the value of adjuvant therapy after esophagectomy is unknown.
Outcomes of Intraoperative Radiotherapy for Locally Advanced Adenocarcinoma of the Esophagogastric Junction After Neoadjuvant Therapy: A Single-Arm, Phase 1 Trial From the Chinese National Cancer Center.
Ann Surg Oncol
December 2024
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: The role of intraoperative radiotherapy (IORT) for adenocarcinoma of the esophagogastric junction (AEG) remains uncertain. Therefore, a prospective phase 1 trial was conducted to assess the safety and feasibility of IORT for locally advanced AEG.
Methods: The study enrolled patients with AEG at stages II-IVA from January 2019 to September 2019.
Gastric Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm: An Unusual Tumor and Its Presentation in a Young Adult.
GE Port J Gastroenterol
December 2024
Department of Gastroenterology, Hospital de Braga, Braga, Portugal.
Article Synopsis
- Gastric cancer, primarily adenocarcinomas, is a leading cause of cancer death, and mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) is one of the rarest subtypes, with significant bleeding occurring in some patients.
- A case study involves a healthy 26-year-old male who had two major gastrointestinal bleeding episodes, leading to the discovery of a 15-mm lesion at the gastroesophageal junction, which was later diagnosed as a mixed adenoneuroendocrine carcinoma.
- Despite its rarity and the lack of established treatment protocols, the patient underwent surgery and chemotherapy, with no evidence of cancer recurrence two years later.
Upper Mediastinal Lymphadenectomy Utilizing Prone-Position Thoracoscopy for Esophageal and Gastroesophageal Junction Cancers.
J Clin Med
November 2024
Upper Gastrointestinal and General Surgery Unit, First Department of Surgery, National and Kapodistrian Universtity of Athens, Laiko General Hospital, 11527 Athens, Greece.
Esophagectomy is the mainstay of treatment in esophageal cancer. Minimally invasive esophagectomy (MIE) remains a challenging procedure and has been associated with a high rate of complications and mortality. Routine lymphadenectomy includes two-field lymphadenectomy for distal-esophageal or gastroesophageal junction Siewert I-II tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!